Press Releases

53-IGC-Pharma-Reports-In-Vitro-Efficacy-of-Molecule-M3
IGC Pharma Reports IGC-M3’s In Vitro Efficacy Against Alzheimer’s – Targeting key Drivers of Disease Progression
Read More →
IIGC-Pharma-to-Present-Three-Posters-on-Artificial-Intelligence
IGC Pharma to Present Advanced AI Platforms for Alzheimer’s Disease at the AAIC 2025
Read More →
IGC-Pharma-Alzheimers-Jag-Rao
IGC Pharma’s Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
Read More →
IGC-Pharma-Introduces-MINT-AD
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer’s Risk and Accelerate Early Detection
Read More →
IGC-Reports-Financial-Results-for-Fiscal-Year-Ended-March-31,-2025
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights – A Year of Transformative Progress in Alzheimer’s Innovation
Read More →
IGC-Pharma-Host-Fiscal-Year-June-25-2025 (1)
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30, 2025
Read More →
IGC-Pharma-Expands-CALMA-Trial-to-Oklahoma
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon 
Read More →
IGC-Pharma-Calma-Phase2-Alzheimer’s-Market
IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market
Read More →
IGC-Pharma-Alzheimers-Melatonin-Toxicity-Safety
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
Read More →
IGC-Pharma-Alzheimers-Innovation-AI-Advisory (2)
IGC Pharma Welcomes Strategic Investment from Advisors
Read More →
IGC-Pharma-Alzheimers-Innovation-AI-Advisory
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer’s Innovation and AI-Driven Programs  
Read More →
IGC-Pharma-Alzheimers-Butler-Hospital-Aging
IGC Pharma Expands CALMA Alzheimer’s Phase 2 Trial with Prestigious Research Site at Butler Hospital’s Memory and Aging Program  
Read More →
IGC-Pharma-Alzheimers-Miami-Jewish-Trial
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health  
Read More →
IGC-Pharma-Alzheimers-Reduction-Sleep-Disturbances
IGC Pharma’s Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances  
Read More →
IGC-Pharma-Alzheimers-Hamilton-Health-Trial
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences    
Read More →
IGC-Pharma-Alzheimers-BayCare-Health-Trial-Florida
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
Read More →